pharmacokinetics
azlocillin
child
cystic
fibrosis
e
r
oxo
imidazolidine
carboxamido
phenyl
acetamido
penicillanic
acid
sodium
salt
azlocillin
securopen
given
dos
mg
kg
body
weight
child
cystic
fibrosis
intravenous
bolus
infection
serum
half
life
h
lower
dose
h
higher
dose
consequent
dose
limited
elimination
kinetics
due
limitation
renal
non
renal
process
elimination
upon
doubling
dose
mg
kg
total
body
clearance
dropped
h
evaluation
data
presented
publication
indicate
dose
limited
elimination
kinetics
normal
situation
azlocillin
besides
serum
concentration
patient
cystic
fibrosis
considerably
lower
seen
healthy
state
reason
faster
elimination
renal
route
cystic
fibrosis
